Fount of Information

AcroBiosystems社 GUCY2C Precision Therapy for Metastatic Colorectal Cancer

この製品に関するご照会・お問合せはこちら
GUCY2C_Precision_Therapy_for_Metastatic_Colorectal_Cancer_1.png

Products

Support

Scientific Talk

COVID-19 R&D

About Us

 

GUCY2C Precision Therapy for Metastatic Colorectal Cancer

 

GUCY2C_Precision_Therapy_for_Metastatic_Colorectal_Cancer_2.jpgCurative therapy has historically been a challenge in colorectal cancer(CRC), with standard therapy relying on a nonspecific, ‘one-size-fits-all model for disease control. GUCY2C-based precision therapy for colorectal cancer offers a promising new outlook in CRC management through improved therapeutic efficacy and enhanced diagnostic accuracy. In contrast to other target antigens, GUCY2C is distinct due to its near-universal expression in CRC and its restricted pattern of expression in endogenous tissues. Collectively, the use of GUCY2C as a therapeutic target shows great potential in cancer vaccine development, CAR-T cell therapy, and the use of monoclonal antibodies.

To support the development of GUCY2C-based precision therapy for colorectal cancer. ACROBiosystems has developed a comprehensive series of GUCY2C protein products, such as PE-labeled, FITC-labeled, and unconjugated GUCY2C, and those proteins are suitable for detecting CAR expression and antibody screening.

 

 

Data Display

 

PE-labeled GUCY2C can specifically detect anti GUCY2C CAR expression

GUCY2C_Precision_Therapy_for_Metastatic_Colorectal_Cancer_3.jpg

5e5 of anti-GUCY2C CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human GUCY2C, His Tag (Cat. No. GUC-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

 

GUCY2C_Precision_Therapy_for_Metastatic_Colorectal_Cancer_4.jpg

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。